Recommendation. CONFLICT OF INTEREST INFORMATION J.R.M. re ILO research funding from Pfizer, Novartis, Bristol Sitagliptin MK-0431 MeyersSquib, pharmaceuticals, and the Aveo is a consultant for Pfizer. D.R.F. is a consultant for Novartis. D.R.L. serves on the advisory boards for Novartis and Pfizer. M.E.L. has a consultant or R with the Advisory Amgen, Bayer, BI, BMS, Genentech, Genzyme, GSK, Hara, Imclone, Lilly, Onyx, OSI, Pfizer, Roche, in patients with myocardial infarction myocardial infarction with ST-segment elevation, is the prime re percutaneous coronary intervention with stent implantation, the treatment of choice according to EU directives and the American College of Cardiology / American Heart Association guidelines. Recommendation for routine stenting in the guidelines are based on studies that have demonstrated the benefits of bare-metal stents in patients with STEMI is based. Although drug-eluting stents have been widely disseminated in unstable angina pectoris and acute myocardial infarction are used, their routinely Cent use in STEMI is still a subject of debate. Randomized clinical trials and meta-analyzes have shown that DES in STEMI and makes stable patients.
IGTE Zielgef Revascularization, with a Hnlichen H FREQUENCY of long-term death or MI. Nevertheless, concerns remain about the long-term safety with increased Hten rates of sp Th events, such as stent thrombosis by vascular pathological responses Wall to DES, especially in acute myocardial infarction. BY such as sirolimus or paclitaxel eluting polymeric support from hunters have a reduction in TVR compared with BMS in stable angina pectoris or non-STEMI patients is shown. Some studies have shown that patients, the SES a significantly lower risk of restenosis, TVR, and MACE compared with patients who had stents paclitaxeleluting. To date, only a few means Ndische randomized studies comparing SES and BMS STEMI, and for other DES, most studies have been selected for Performed hlten patients. Glycoprotein IIb / IIIa inhibitors are the meters Antiplatelet drugs Piazza Barberini. Glycoprotein IIb / IIIa inhibitors are widely used in patients with STEMI examined before or after PCI. But studies of routinely Cent use of abciximab in STEMI results were not received uniforms. The question remains whether the routinely Owned administration of abciximab still has other advantages, especially when clopidogrel is used. We have developed Debater U test, the superiority of SES over BMS in unselected patients with STEMI prime Ren underwent PCI and the superiority of abciximab Abciximab in one of the Ra to examine clopidogrel. Study design and methods.
The study was investigatorinitiated a Debater, prospective, randomized, open second February factorial study with independent Ngigen data management, statistical analysis, assessment and evaluation criteria in blind patients from 10 centers who underwent primary regional focus Ren PCI to a PCI buy Linezolid center only. The study was initiated and coordinated by the Catharina Hospital Eindhoven, Department of Biostatistics, Academic Medical Center of the University of t Amsterdam. The Steering Committee was responsible for the design, implementation and reporting of the study. Data management and analysis were carried out in collaboration with the Academy of Amsterdam University Medical Center. The study was approved by the Ethics Commission. All authors analyzed and the angled Nderten.